High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations

Immunotherapy with checkpoint inhibitors, such as antibodies blocking the programmed cell-death receptor-1 (PD-1), has resulted in remarkable responses in patients having traditionally refractory cancers. Although response to PD-1 inhibitors correlates with PD-1 ligand (PD-L1 or PD-L2) expression, P...

Descripción completa

Detalles Bibliográficos
Autores principales: Boichard, Amélie, Tsigelny, Igor F., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384346/
https://www.ncbi.nlm.nih.gov/pubmed/28405512
http://dx.doi.org/10.1080/2162402X.2017.1284719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384346/
https://www.ncbi.nlm.nih.gov/pubmed/28405512
http://dx.doi.org/10.1080/2162402X.2017.1284719

Ejemplares similares